

RECEIVED

FEB 15 2001

~~structure of the peptide, oligopeptide, or protein inhibitor~~ TECH CENTER 1600/2900
~~is such that one or more arginine groups are available to the~~
~~nitric oxide synthase.~~

Please cancel claim 2.

~~3. (Amended)~~

*A²
sub
B²*
~~The method of claim 1, wherein the [inhibitor] peptide,~~
~~oligopeptide, or protein is [N^{ω} -methyl-L-arginine] selected~~
~~from the group consisting of L-Arginine, Poly-Arginine, BK,~~
~~Des-Arg¹-BK, Des-Arg⁹-BK, BK fragment 1-7, BK fragment 2-7,~~
~~[Lys¹]-BK, Lys-BK, Ile-Ser-BK, and Met-Lys-BK.~~

✓ ✓ ✓
Please cancel claims 4, 7 and 8.

~~10. (Amended)~~

*A³
sub
B³*
~~A method of preventing or treating a nitric oxide-~~
~~mediated disease or condition in a mammalian subject~~
~~comprising administering to the subject in need of such~~
~~prevention or treatment [a therapeutically effective amount]~~
~~from about 20-500 μ g/kg of a peptide, oligopeptide, or protein~~
~~[inhibitor of] that acts as a substrate for or an inhibitor of~~
~~nitric oxide synthase.~~

Please cancel claim 12.

RECEIVED

FEB 15 2001

13. (Amended)

*sub
B
A⁴*
The method of claim 10, wherein the [inhibitor] peptide, oligopeptide, or protein is [N^{G} -methyl-L-arginine] selected from the group consisting of L-Arginine, Poly-Arginine, BK, Des-Arg1-BK, Des-Arg9-BK, BK fragment 1-7, BK fragment 2-7, [Lys1]-BK, Lys-BK, Ile-Ser-BK, and Met-Lys-BK.

Please cancel claim 14.

A⁵
16. (New)

*sub
B⁵*
A method of regulating or controlling nitric oxide production in a mammalian subject comprising administering to the mammal from about 20-500 $\mu\text{g}/\text{kg}$ of a peptide, oligopeptide, or protein that acts as a substrate for a nitric oxide synthase, whereby the tertiary structure of the peptide, oligopeptide, or protein inhibitor is such that one or more arginine groups are available to the nitric oxide synthase, said peptide, oligopeptide or protein being selected from the group consisting of L-Arginine, Poly-Arginine, BK, Des-Arg1-BK, Des-Arg9-BK, BK fragment 1-7, BK fragment 2-7, [Lys1]-BK, Lys-BK, Ile-Ser-BK, and Met-Lys-BK.

REMARKS

I. Claim Rejections - 35 U.S.C. 112, First Paragraph

Claims 1-15 were rejected under 35 U.S.C. § 112, first paragraph, as being based on a disclosure that is not